The use of citalopram in Irritable bowel syndrome: A prospective study

Amaç: İrritabl Barsak Sendromu (İBS) yaygın görülen bir durumdur. Medikal tedavisinde antidepresanlarve antispazmotikler kullanılır. Çalışmamızda, selektif serotonin reuptake inhibitörü (SSRI) grubundan birantidepresan olan sitalopramın, İBS semptomları ve depresyon- anksiyete skorları üzerine etkisiniaraştırmayı amaçladık.Materyal ve Metot: Çalışmaya, Roma 3 tanı kriterlerine göre İBS tanısı konan 103 hasta alındı. İBS'lihastalar, 3 gruba bölündü: 1. grupta (n=29) Beck Depresyon Skoru (BDS) ve Beck Anksiyete Skoru (BAS)minimal- hafif derecede olan hastalara, bir antispazmotik olan otilonyum bromide 120 mg/gün verildi. 2.grupta (n=41) BDS ve BAS orta- ciddi olanlara, otilonyum bromid 120 mg/gün ve sitalopram 20 mg/günverildi. 3. grupta (n=33) ise yine BDS ve BAS orta- ciddi olanlara, sadece otilonyum bromid 120 mg/günverildi. 3 aylık tedavinin sonunda, tedavi cevapları İBS şiddeti skorlama sistemi ve BDS- BAS iledeğerlendirildi.Bulgular: Tedavi sonunda 1. ve 2. gruplarda BDS ve BAS'larda anlamlı düzelmeler olurken (p0,05). İBS şiddet skorlarında ise, 1. grupta dahabelirgin olmak üzere, her üç grupta da istatistiksel olarak anlamlı azalmalar oldu (p0,05).Sonuç: Bulgularımıza göre, İBS'li hastalardaki depresyon ve anksiyete şiddetli değilse, bu hastalarıntedavisinde tek başına antipazmotik verilmesi, uygun bir seçenek olabilir.

İrritabl Barsak sendromu 'nda sitalopram kullanımı

Background: Irritable Bowel Syndrome (IBS) is a commonly seen condition. Medications used in itstreatment include anti-depressants and anti-spasmotics. This study aimed to examine the effect ofcitalopram, a selective serotonin reuptake inhibitor groupped antidepressant on IBS symptoms anddepression-anxiety scores.Materaial and Methods: 103 patients diagnosed with IBS according to the Rome 3 diagnostic criteria wereincluded in the study. Patientswith IBS were divided into three groups:those with minimal-mild BeckDepression Score (BDS) and Beck Anxiety Score (BAS) were only given otilonium bromide 120 mg/day(group 1, n=29), those with moderate- severe scores were given otilonium bromide120 mg/day andcitalopram20 mg/day (group 2, n=41) and those with moderate- severe scores were only given otiloniumbromide 120 mg/day (group 3, n=33). At the end of 3 months treatment, the responses to treatment wereevaluated with the IBS severity scoring system and BDS-BAS.Results: While a significant improvement was detected in the BDS and BAS of first and second groups .(p0,05).Statisticallysignificant improvementwas found in IBS severity score of three groups (p0,05).Conclusion: According to our findings, if depression and anxiety in IBS patients are not so severe, atreatment regime with only anti-spasmotics may be an appropriate choice.

PDF

___

1) Wells NE, Hahn BA, Whorwell PJ. Clinical economics review: irritable bowel syndrome. Aliment Pharmacol Ther. 1997;11(2):1019-30.
2) Garakani A, Win T, Virk S, Gupta S, Kaplan D, Masand PS. Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther. 2003;10(3):61-7.
3) Talley NJ. Irritable Bowel Syndrome. Intern Med J. 2006;36(1):724-8.
4) Musial F, Hauser W, Langhorst J, Dobos G, Enck P. Psychophysiology of visceral pain in IBS and health. J Psychosom Res. 2008;64(3):589-97.
5) Talley NJ, Spiller R. Irritable bowel syndrome: a little understood organic bowel disease? Lancet. 2002;360(4):555-64.
6) Spiller R. Serotonin, inflammation, and IBS: fitting the jigsaw together? J Pediatr Gastroenterol Nutr. 2007;45(4):115-9.
7) Piche T, Saint-Paul MC, Dainese R, Marine BE, Iannelli A, Montoya ML, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut. 2008;57(2):468-73.
8) Heitkemper M, Jarrett M, Cain K, Shaver J, Bond E, Woods NF, et al. Increased urine cathecolamines and cortisol in women with irritable bowel syndrome. Am J Gastroenterol. 1996;91(5):906-13.
9) Colucci R, Blandizzi C, Bellini M, Ghisu N, Tonini M, Del TM. The genetics of the serotonin transporter and irritable bowel syndrome. Trends Mol Med. 2008;14(4):295-304.
10) Crowell MD. Role of serotonin in the pathophysiology of the irritable bowel syndrome. Br J Pharmacol. 2004;141(6):1285-93.
11) Creed F, Guthrie E. Psychological factors in the irritable bowel syndrome. Gut. 1987;28(2):1307-18.
12) Lydiard B. Irritable bowel syndrome, anxiety, and depression: what are the links? J Clin Psychiatry. 2001;62(1):38-45.
13) Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut. 2002;51(3):29-33.
14) Frederic RC. Irritable Bowel Syndrome and Antidepressants. J Manag Care Pharm.2008;14(4):882- 5.
15) Garvin B, Wiley JW. The role of serotonin in irritable bowel syndrome: implications for management. Curr Gastroenterol Rep.2008;10(3):363-8.
16) Hayee B, Forgacs I. Psychological approach to managing irritable bowel syndrome. BMJ.2007;334(5):1105-9.
17) Bahar RJ, Collins BS, Steinmetz B, Ament ME. Double-blind placebo-controlled trial of amitriptyline for the treatment of irritable bowel syndrome in adolescents. J Pediatr. 2008; 152(2):685-9.
18) Trinkley KE, Nahata MC. Treatment of irritable bowel syndrome. J Clin Pharm Ther. 2011;36(4):275-82.
19) Quartero A, Meineche SV, Muris JW, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst Rev. 2011. Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.C D003460.pub3/abstract
20- Drossman DA, Corrazziari E, Delvaux M, Spiller R, Talley NJ, Thompson WG, et al. Guidelines - Rome III Diagnostic Criteria for Functional Gastrointestinal Disorders. J Gastrointestin Liver Dis. 2006;15(5):307- 12.
21) Beck AT. An inventory for measuring depression. Arch Gen Psychiatry. 1961;4(1):561-71.
22) Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: Psychometric properties. J Consult Clin Psychol. 1988;56(2):893-7.
23) Hisli N. Reability and validity of Beck Depression Inventory among university students. Turk J Psychol. 1989;7(1):3-13.
24) Ulusoy M, Erkmen H, Sahin N. Turkish version of the Beck Anxiety Inventory: psychometric properties. J Cogn Psychother. 1998;12(2):163-72.
25) Kilinc S, Torun F. Depression Rating Scales Used in Clinical Practice in Turkey. Dirim Medical Journal 2011;1(3):139-49.
26) Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997;11(2):395-402.
27) Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med.2000;108(4):65-72.
28) Farthing MJ. Treatment of irritable bowel syndrome. BMJ.2005;330(5):429-30.
29) Baldessarini RJ. Drug therapy of depression and anxiety disorders. Goodman & Gilman's The Pharmacologic Basis of Therapeutics. 2010;28(6):221-6.
30) Charles DG, Mary JG, Richard AA, Abhijit C, Christine D, Pierre P, et al. Irritable bowel syndrome: an international study of symptoms in eight countries. Eur J Gastroenterol Hepatol. 2008;20(4):659-67.
31) Megan F, Sarah EG, Geoffrey CW. Effects of Antidepressants in Patients With Irritable Bowel Syndrome and Comorbid Depression. Clin Ther. 2010;32(3):1221-33.
32) Ladabaum U, Sharabidze A, Levin TR, Zhao WK, Chung E, Bacchetti P, et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel sydrome. Clin Gastroenterol Hepatol. 2010;8(1):42-8.
33) Tack j, Broekaert d, Fischler b, Oudenhove lv, Gevers am, Janssens j. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(2):1095-103.
34) Talley NJ, Kellow JE, Boyce P, Tennant C, Huskic S, Jones M. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Dig Dis Sci. 2008;53(1):108-15.
35) Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1(3):219-28.
36) Vahedi H, Merat S, Rashidioon A, Ghoddoosi A, Malekzadeh R. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22(4):381-5.
37) Lesbros PD, Michetti P, Fried M, Beglinger C, Blum AL. Meta-analysis: the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2004;20(2):1253-69.
38) Fock KM, Chew CN, Tay LK, Peh LH, Chan S, Pang EPH. Psychiatric illness, personality traits and the irritable bowel syndrome. Ann Acad Med Singapore. 2001;30(5):611-4.